论文部分内容阅读
目的：评价孟鲁司特联用布地奈德对儿童咳嗽变异型哮喘的有效性和安全性。方法在PubMed、EMBASE、CENTRAL、CBM和CNKI等数据库中检索从创建以来至2014年3月关于孟鲁司特联用布地奈德治疗儿童咳嗽变异型哮喘的随机对照试验的文献，由研究人员对文献进行筛选和数据提取，并用RevMan 5.0进行Meta分析。结果纳入19项研究，1357例儿童咳嗽变异型哮喘，其中孟鲁司特联用布地奈德组812例和对照组792例，Meta分析显示院两组近期有效率、肺功能改善情况(FEV1、PEF)、随访复发情况孟鲁司特联用布地奈德组与对照组有显著统计学差异(<0.01)，而对于不良反应发生情况，两组相比无显著统计学意义(=0.21)；且无严重不良反应发生。结论孟鲁司特联用布地奈德治疗儿童咳嗽变异型哮喘可以提高患儿临床有效率，改善肺功能，减少复发率，并且未显著增加不良反应发生率，但仍然需要开展更多高质量的多中心、大样本、前瞻性、随机、双盲临床试验加以进一步验证。“,”Objective To evaluate the effectiveness and safety of Montelukast combined with Budesonide in the treatment of children`s cough variant asthma.Methods The PubMed,EMBASE, CENTRAL, CBM and CNKI were searched up from established to March, 2014 , to find the clinical random controlled trials of Montelukast combined with Budesonide for the disease of children with cough variant asthma, references and dates were filtered and extracted by researchers literature,and meta analysis with RevMan 5.0. Results 19 clinical trials with 1357 cases were included in total. 812 patients were in Montelukast combined with Budesonide group, 792 patients were control group. Meta analysis indicated that the clinical efficiency, lung function(FEV1、PEF)and the recurrent rate after follow-up in the experimental group were superior to the control group and the differences were statistically significant ( <0.01). Although there were no statistically significant ( =0.21)between the two groups in adverse reaction, there was no seriously adverse effect. Conclusion Montelukast combined with Budesonide can improve the clinical efficiency and lung function and reduce recurrence rate for children with cough variant asthma, in addition, there were no obviously adverse reactions after its treatment. However, it is necessary to carry out more multi center, high quality, large sample, prospective, randomized, double blind clinical trials for further validation.